VFA
ATNM icon

Virtus Fund Advisers’s Actinium Pharmaceuticals ATNM Stock Holding History

Virtus Fund Advisers’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-56
Closed -$12K – 1217
2014
Q2 		$12K Buy
+56
New +$18.6K ﹤0.01% 2700

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return
PP
Patten & Patten Chattanooga, Tennessee $1.66B AUM 18.12% 1-Year Est. Return

Virtus Fund Advisers's ATNM Position: Q3 2014 in Review

Virtus Fund Advisers sold out of Actinium Pharmaceuticals (ATNM) in Q3 2014, closing a stake of 56 shares — an estimated $12K sold.

Virtus Fund Advisers first reported a position in ATNM in Q2 2014 and held it in 1 quarter. The position peaked at $12K in Q2 2014. 34 funds tracked by Wall St. Rank hold ATNM as of Q3 2014.

  • Virtus Fund Advisers reported no remaining Actinium Pharmaceuticals position as of Q3 2014 after selling out during the quarter.
  • Virtus Fund Advisers sold 56 Actinium Pharmaceuticals shares in Q3 2014, an estimated $12K.
  • Virtus Fund Advisers first reported a position in Actinium Pharmaceuticals in Q2 2014 and held it in 1 quarter.
  • Virtus Fund Advisers's Actinium Pharmaceuticals position peaked at $12K in Q2 2014.
  • 34 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2014.

Based on Virtus Fund Advisers's 13F filing for Q3 2014, filed 31 Oct 2014.